Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Acromegaly, Neuroendocrine Tumours
Both
Acromegaly, Neuroendocrine Tumours
Trial Information
Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
Inclusion Criteria:
- Written informed consent (also mandatory in case of retrospective documentation of
subject data)
- Diagnosis of acromegaly or NET with the intention to be treated with ATG or already
on treatment with ATG
Exclusion Criteria:
- The subject has already been included in this study
- Participation in an interventional trial
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)
Outcome Time Frame:
Baseline and 1 year
Safety Issue:
No
Principal Investigator
Philipp Hoffmanns, MD, PhD, MBA
Investigator Role:
Study Director
Investigator Affiliation:
Ipsen
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
A-94-52030-240
NCT ID:
NCT01840449
Start Date:
June 2012
Completion Date:
December 2017
Related Keywords:
- Acromegaly
- Neuroendocrine Tumours
- Acromegaly
- Neuroendocrine Tumors
Name | Location |
|---|
